Mitsutaka Okuda

Two chronic myelogenous leultaemia cell lines which represent different stages of erythroid differentiation

Summary We established two cell lines, YN‐1 and Y‐1K. from the peripheral blood of two chronic myelogenous leukaemia patients in blastic crisis. Characterization of the YN‐1 and Y‐1K cells revealed that these cells expressed erythroid lineage markers. However, there was a marked difference in the level of γ‐globin mRNA and haenioglobin in YN‐1 and Y‐1K cells. YN‐1 contained approximately 1–5% benzidine‐positive staining cells, whereas no benzidine‐positive cells were observed in Y‐1K cells. Haemoglobin production in YN‐1 cells was markedly increased with various chemical inducers of erythroid differentiation, but was not in Y‐1K cells. In contrast, Y‐1K cells expressed CD34 stem cell antigen and CD41 megakaryocyte‐specific antigen. These observations suggested that, although both cell lines were committed to the erythroid lineage. each cell line represented a distinct differentiation stage in the erythroid differentiation programme. Y‐1K seemed to correspond to an early stage of cells in erythroid lineage, whereas YN‐1 represented a more advanced stage in human erythropoiesis.

A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression

Bortezomib is approved for the treatment of patients with relapsed or refractory multiple myeloma (MM), but only a few clinical studies for Japanese patients who were treated with bortezomib have been reported. We retrospectively analyzed 40 patients with relapsed or refractory MM who have received bortezomib at three collaborating centers in Miyagi prefecture in Japan. All the patients have been received bortezomib in combination with dexamethasone. Responses were determined using International Myeloma Working Group uniform response criteria. The overall response was observed in 30 patients (75%), including very good partial response in 8 patients (20%), and partial response in 22 patients (55%). The median time to disease progression was 8.7 months, and the median overall survival has not been reached. The factors affecting time to disease progression were International Staging System stage, serum β2-microglobulin level, and number of treatment cycles. The most common grade 3 and 4 adverse events were thrombocytopenia (50%), peripheral neuropathy (25%), leukopenia (25%), and herpes zoster infection (25%). Thus, bortezomib is well tolerated and effective for Japanese patients with relapsed or refractory MM. Our results suggest that serum β2-microglobulin level may be a marker of prognosis on bortezomib therapy for patients with relapsed or refractory MM although further studies are needed.